Beige Fat May Hold Key to Blood Pressure Control, Mouse Study Suggests

Researchers at Rockefeller University have identified a surprising biological mechanism that could reshape how doctors approach high blood pressure: beige fat, the metabolically active tissue that burns calories, appears to actively suppress the enzymes and proteins that drive hypertension. The finding emerged from a mouse study published in Science and suggests that the absence of beige fat—common in people with obesity—may be a direct contributor to elevated blood pressure, not merely a side effect.

The scale of the problem is enormous. According to the World Health Organization, approximately 1.4 billion adults worldwide had high blood pressure in 2024. Hypertension remains the leading risk factor for death globally and accounts for nearly half of all deaths from heart disease and stroke. While doctors have long understood that obesity increases hypertension risk, the specific biological pathway connecting the two has remained unclear. Most attention has focused on white fat, the energy-storing tissue that accumulates in the body during weight gain. But this new work suggests the real culprit may be what's missing: beige fat, which burns energy to produce heat rather than storing it.

To test this theory, the research team genetically engineered mice so they could not produce beige fat by removing the Prdm16 gene from their fat cells. The results were striking. Mice without beige fat began expressing markers of white fat, including angiotensinogen, a protein precursor that triggers hormones known to raise blood pressure. More tellingly, the fat surrounding the blood vessels in these mice accumulated white fat characteristics, and the animals developed elevated blood pressure, increased arterial stiffness, and fibrous tissue buildup around their vessels—all hallmarks of vascular disease. The mice also became hypersensitive to angiotensin II, a powerful vasoconstrictor that narrows blood vessels.

Mascha Koenen, the study's first author and a postdoctoral fellow at Rockefeller, explained the distinction between fat types in plain terms: white adipocytes store excess energy as lipids, while beige and brown adipocytes burn energy to generate heat when activated. "Humans with thermogenic fat have a lower prevalence of cardiovascular and metabolic diseases, including hypertension and diabetes," Koenen told Medical News Today. The team focused on beige fat specifically because it closely resembles the heat-producing fat found in adult humans, making the mouse findings potentially translatable to people.

The breakthrough came when researchers identified a specific enzyme called QSOX1 that beige fat naturally suppresses. When Prdm16 is deleted and beige fat cannot form, QSOX1 levels spike dramatically. This enzyme appears to be a key driver of vascular fibrosis and the heightened sensitivity to vasoconstrictors that leads to elevated blood pressure. When the team deleted both Prdm16 and Qsox1 in the mice's fat cells, they prevented the vascular damage and blood pressure elevation entirely. "QSOX1 is an enzyme, so it could represent a new therapeutic target for blood pressure regulation in individuals lacking thermogenic fat," Koenen said.

Paul Cohen, the senior author and head of the Laboratory of Molecular Metabolism at Rockefeller, framed the work as a bridge between human observation and animal science. Earlier research had shown that people with active thermogenic fat had lower rates of hypertension than those without it, but whether this was cause or effect remained unknown. "We used a reverse translational approach to model this observation from humans in mouse models," Cohen explained. The discovery that modifying only fat cells produced effects on blood vessels suggests a direct communication between adipose tissue and the vascular system—a crosstalk that had not been fully appreciated before.

The implications are substantial. If QSOX1 can be targeted pharmacologically, it might offer a new avenue for treating hypertension in people who lack sufficient beige fat. The researchers are now investigating how QSOX1 regulates vascular fibrosis and whether thermogenic fat might influence other forms of cardiovascular disease. For the millions of people taking blood pressure medications, this work hints at a fundamentally different approach: not just managing the symptom, but restoring the metabolic tissue that naturally keeps blood pressure in check.